Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27850598 | 0.73 | TSHR (0.33) | TSHRTDP1 | |
| SCHEMBL1325981 | 0.73 | — | — | |
| SCHEMBL1326087 | 0.71 | TSHR (0.38) | TSHRTDP1 | |
| SCHEMBL42436 | 0.69 | — | — | |
| SCHEMBL3217073 | 0.69 | TSHR (0.43) | TSHRTDP1 | |
| SCHEMBL9433116 | 0.67 | — | — | |
| SCHEMBL5833314 | 0.65 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL25280700 | 0.64 | — | — | |
| SCHEMBL17024486 | 0.64 | TSHR (0.38) | TSHRTDP1 | |
| SCHEMBL25236500 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113906036-B | Polycyclic aromatic compound, material for organic device, organic electroluminescent element, display device, and lighting device | 学校法人关西学院 | 2024-10-25 | — | — | CN | disclosed |
| US-8058261-B2 | 3′-ethynylcytidine derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-15 | — | — | US | disclosed |
| EP-2045258-B1 | 3'-ETHYNYLCYTIDINE DERIVATIVE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-7825103-B2 | 5'-O-triisopropylsilyl-2'-cyano-2'-deoxy-1- beta -D-arabinofuranosylcytosine; antitumor agents | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| US-20090306008-A1 | 3'-ETHYNYLCYTIDINE DERIVATIVE | Sasaki, Takuma (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090118222-A1 | NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2045258-A1 | 3'-ETHYNYLCYTIDINE DERIVATIVE | Taiho Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-1845102-A1 | NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-5317100-A | Process for the preparation of optically active acyloxyazetidinones | CIBA-GEIGY CORP. (US) | 1994-05-31 | — | — | US | disclosed |
| EP-0181831-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE ACYLOXYAZETIDINONES | CIBA-GEIGY AG (CH) | 1993-08-25 | — | — | EP | disclosed |
| EP-0367722-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE ACYLOXYAZETIDINONES | CIBA-GEIGY AG (CH) | 1993-05-19 | — | — | EP | disclosed |
| EP-0126709-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE AZETIDINONES | CIBA-GEIGY AG (CH) | 1991-04-03 | — | — | EP | disclosed |
| EP-0367722-A1 | Process for preparing optically active acyloxyazetidinones | CIBA-GEIGY AG (CH) | 1990-05-09 | — | — | EP | disclosed |
| US-4614614-A | Process for the manufacture of optically active azetidinones | CIBA-GEIGY CORPORATION (US) | 1986-09-30 | — | — | US | disclosed |
| EP-0181831-A2 | Process for the preparation of optically active acyloxyazetidinones | CIBA-GEIGY AG (CH) | 1986-05-21 | — | — | EP | disclosed |
| EP-0126709-A1 | Process for the preparation of optically active azetidinones | CIBA-GEIGY AG (CH) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118222-A1 | NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT | CDK10, SRSF9, SNRPD1 | TSHR 2261/4885TDP1 1736/4885 |
| US-20090306008-A1 | 3'-ETHYNYLCYTIDINE DERIVATIVE | SLC7A1, SLC29A1, SLC26A3 | TSHR 719/4885TDP1 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.